|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K 16/2803 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K2039/505 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61K2039/545 | (2013.01) |
| (11) | Number of the document | 3697817 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18800381.8 |
| Date of filing the European patent application | 2018-10-18 | |
| (97) | Date of publication of the European application | 2020-08-26 |
| (45) | Date of publication and mention of the grant of the patent | 2022-10-05 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2018/056441 |
| Date | 2018-10-18 |
| (87) | Number | WO 2019/079548 |
| Date | 2019-04-25 |
| (30) | Number | Date | Country code |
| 201762573835 P | 2017-10-18 | US |
| (72) |
TAKIMOTO, Chris Hidemi, Mizufune , US
CHAO, Mark, Ping , US
VOLKMER, Jens-Peter , US
|
| (73) |
Forty Seven, Inc. ,
333 Lakeside Drive, Foster City, CA 94404,
US
|
| (54) | ANTI-CD47 AGENT-BASED OVARIAN CANCER THERAPY |
| ANTI-CD47 AGENT-BASED OVARIAN CANCER THERAPY |